Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abraxane + Bevacizumab dosing schedules in metastatic breast cancer
NCT00281528Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Feb 2006
- Primary completion
- Jul 2010
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of nab-paclitaxel in breast cancer (3 arms), sponsored by Celgene Corporation. Primary endpoints: Objective Response Rate (CR + PR) up to 43 months, Most Severe Grade for Absolute Neutrophil Count up to 54 months and 6 more. Started Feb 2006; status: terminated.
02
Drugs
nab-paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00281528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00281528.